Jump to content

KannaLife: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
No edit summary
Line 27: Line 27:
* [http://www.pabiotechbc.org/biotech/directory.htm Pennsylvania Biotechnology Center]
* [http://www.pabiotechbc.org/biotech/directory.htm Pennsylvania Biotechnology Center]
* [http://kannalife.com Official Website]
* [http://kannalife.com Official Website]
* [http://cannabidial.com/tag/kannalife]

==References==
==References==
{{Reflist}}
{{Reflist}}

Revision as of 15:53, 25 January 2015

KannaLife Sciences Inc.
Company typeSubsidiary
IndustryPharmaceutical
Founded2010
HeadquartersDoylestown, Pennsylvania And West Hills, New York
Total assetsExclusive License of patent US 6630507 
Websitehttp://kannalife.com
KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent US 6630507  “Cannabinoids as Antioxidants and Neuroprotectants."

KannaLife Sciences Inc. is a bio-pharmaceutical and phyto-medical company based in West Hills, NY and Doylestown, PA. KannaLife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Its parent company is Medical Marijuana, Inc..[1]

In 2011, the company was granted an Exclusive License[2] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507 , “Cannabinoids as Antioxidants and Neuroprotectants."[3]

KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County[4] in Doylestown, PA, for a target drug candidate to treat Hepatic encephalopathy, an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.

References

  1. ^ Leland, John (October 31, 2014). "For Pot Inc., the Rush to Cash In Is Underway". The New York Times. Retrieved 9 January 2015.
  2. ^ "Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans". federalregister.gov. Retrieved 2011-11-17.
  3. ^ "KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT)". thestreet.com. Retrieved 2012-07-09.
  4. ^ "KannaLife in R&D Collaboration for Cannabinoid-Based Drugs". Genengnews.com. Retrieved 2013-04-04.